Brelovitug 300 mg

DRUG3 trials

Sponsors

Mirum Pharmaceuticals, Inc.

Conditions

Chronic Hepatitis D Infection

Phase 2

A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

Active, not recruitingNCT06907290

Mirum Pharmaceuticals, Inc.Chronic Hepatitis D Infection

Start: 2025-03-25End: 2029-09-01Target: 150Updated: 2026-03-02

Phase 3

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

RecruitingNCT07200908

Mirum Pharmaceuticals, Inc.Chronic Hepatitis D Infection

Start: 2025-08-27End: 2029-09-30Target: 172Updated: 2026-08-25

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Active, not recruitingNCT07298330

Mirum Pharmaceuticals, Inc.Chronic Hepatitis D Infection

Start: 2026-01-14End: 2029-01-01Target: 80Updated: 2026-06-29